Compare · JUNS vs NVO
JUNS vs NVO
Side-by-side comparison of Jupiter Neurosciences Inc. (JUNS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JUNS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $217.28B, about 25312.4x JUNS ($8.6M).
- Over the past year, JUNS is down 94.0% and NVO is down 27.0% - NVO leads by 67.0 points.
- JUNS has been more active in the news (15 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for JUNS).
- Company
- Jupiter Neurosciences Inc.
- Novo Nordisk A/S
- Price
- $0.18-2.84%
- $49.08-0.41%
- Market cap
- $8.6M
- $217.28B
- 1M return
- -20.35%
- +11.62%
- 1Y return
- -94.02%
- -27.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 15
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest JUNS
- Chief Administrative Officer Rosen Alexander Gustaf Erik converted options into 261,161 shares, increasing direct ownership by 73% to 617,411 units (SEC Form 4)
- Director Kampf Julie B. converted options into 82,875 shares (SEC Form 4)
- Director Weis Holger converted options into 85,800 shares, increasing direct ownership by 796% to 96,581 units (SEC Form 4)
- Director Hemmerly Nicholas H. converted options into 95,550 shares (SEC Form 4)
- Chief Scientific Officer Hayward Marshall A. converted options into 1,014,195 shares, increasing direct ownership by 51% to 2,995,077 units (SEC Form 4)
- SEC Form EFFECT filed by Jupiter Neurosciences Inc.
- Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
- SEC Form 4 filed by Director Philipson Tomas Jan
- SEC Form 3 filed by new insider Philipson Tomas Jan
- SEC Form 424B3 filed by Jupiter Neurosciences Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S